ADC Therapeutics S.A.
General ticker "ADCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $536.3M (TTM average)
ADC Therapeutics S.A. follows the US Stock Market performance with the rate: 11.1%.
Estimated limits based on current volatility of 2.2%: low 0.99$, high 1.12$
Factors to consider:
- Total employees count: 193 as of 2025
- US accounted for 99.3% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Product liability, Operational and conduct risks, Regulatory and compliance, Supply chain disruptions, Manufacturing risks
- Current price 56.7% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.56$, 6.87$]
- 2026-12-31 to 2027-12-31 estimated range: [2.46$, 6.57$]
Financial Metrics affecting the ADCT estimates:
- Positive: with PPE of -3.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0.09 > -0.60
- Positive: Inventory ratio change, % of -15.72 <= -0.75
- Negative: negative Net income
Short-term ADCT quotes
Long-term ADCT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $69.56MM | $70.84MM | $81.36MM |
| Operating Expenses | $235.54MM | $201.49MM | $202.86MM |
| Operating Income | $-165.99MM | $-130.65MM | $-121.50MM |
| Non-Operating Income | $-29.43MM | $-25.48MM | $-20.11MM |
| Interest Expense | $46.33MM | $50.21MM | $51.63MM |
| R&D Expense | $127.13MM | $109.63MM | $104.00MM |
| Income(Loss) | $-195.42MM | $-156.14MM | $-141.61MM |
| Taxes | $39.11MM | $0.17MM | $1.01MM |
| Other Income(Loss) | $-5.53MM | $-1.54MM | $0.00MM |
| Net Income(Loss)* | $-240.05MM | $-157.85MM | $-142.62MM |
| Stockholders Equity | $-148.25MM | $-202.64MM | $-185.83MM |
| Inventory | $16.18MM | $18.39MM | $4.18MM |
| Assets | $354.78MM | $321.98MM | $323.15MM |
| Operating Cash Flow | $-118.69MM | $-123.83MM | $-141.17MM |
| Capital expenditure | $3.22MM | $0.87MM | $0.26MM |
| Investing Cash Flow | $-3.22MM | $-0.87MM | $0.40MM |
| Financing Cash Flow | $73.88MM | $97.05MM | $150.94MM |
| Earnings Per Share** | $-2.94 | $-1.62 | $-1.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.